Symbols / CSTL Stock $25.10 +2.12% Castle Biosciences, Inc.
CSTL (Stock) Chart
About
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Stock Fundamentals
Scroll to Statements| Market Cap | 760.43M | Enterprise Value | 483.76M | Income | -24.16M | Sales | 344.23M | Book/sh | 15.86 | Cash/sh | 10.07 |
| Dividend Yield | — | Payout | 0.00% | Employees | 883 | IPO | — | P/E | — | Forward P/E | -45.95 |
| PEG | — | P/S | 2.21 | P/B | 1.58 | P/C | — | EV/EBITDA | -237.25 | EV/Sales | 1.41 |
| Quick Ratio | 5.01 | Current Ratio | 5.26 | Debt/Eq | 7.86 | LT Debt/Eq | — | EPS (ttm) | -0.83 | EPS next Y | -0.55 |
| EPS Growth | — | Revenue Growth | 0.80% | Earnings | 2026-05-06 | ROA | -2.56% | ROE | -5.21% | ROIC | — |
| Gross Margin | 79.37% | Oper. Margin | -4.40% | Profit Margin | -7.02% | Shs Outstand | 30.30M | Shs Float | 25.26M | Short Float | 5.19% |
| Short Ratio | 4.47 | Short Interest | — | 52W High | 44.28 | 52W Low | 14.59 | Beta | 1.19 | Avg Volume | 386.20K |
| Volume | 214.23K | Target Price | $47.25 | Recom | Strong_buy | Prev Close | $24.58 | Price | $25.10 | Change | 2.12% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-20 | main | Canaccord Genuity | Buy → Buy | $40 |
| 2026-02-27 | main | Baird | Outperform → Outperform | $44 |
| 2026-01-26 | main | Guggenheim | Buy → Buy | $47 |
| 2026-01-12 | main | Lake Street | Buy → Buy | $52 |
| 2026-01-05 | main | Guggenheim | Buy → Buy | $43 |
| 2025-12-22 | main | Canaccord Genuity | Buy → Buy | $50 |
| 2025-12-12 | main | BTIG | Buy → Buy | $50 |
| 2025-11-05 | main | BTIG | Buy → Buy | $38 |
| 2025-11-04 | main | Baird | Outperform → Outperform | $41 |
| 2025-09-09 | main | Canaccord Genuity | Buy → Buy | $37 |
| 2025-05-21 | main | Scotiabank | Sector Outperform → Sector Outperform | $40 |
| 2025-05-06 | main | Lake Street | Buy → Buy | $35 |
| 2025-05-06 | main | Canaccord Genuity | Buy → Buy | $37 |
| 2025-02-28 | main | Baird | Outperform → Outperform | $37 |
| 2025-01-02 | reit | Stephens & Co. | Overweight → Overweight | $41 |
| 2024-11-06 | main | Scotiabank | Sector Outperform → Sector Outperform | $44 |
| 2024-11-05 | main | Lake Street | Buy → Buy | $40 |
| 2024-11-05 | main | Keybanc | Overweight → Overweight | $36 |
| 2024-11-05 | main | Baird | Outperform → Outperform | $39 |
| 2024-10-29 | main | Canaccord Genuity | Buy → Buy | $42 |
- New data suggest some early melanomas carry higher relapse risk - Stock Titan ue, 21 Apr 2026 11
- Castle Biosciences, Inc. (CSTL) Stock Analysis: A 97% Upside Potential Beckons Investors - DirectorsTalk Interviews Fri, 17 Apr 2026 09
- Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance Mon, 09 Feb 2026 08
- CSTL Maintained by Canaccord Genuity -- Price Target Lowered to $40 - GuruFocus Mon, 20 Apr 2026 19
- Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside (NASDAQ:CSTL) - Seeking Alpha Mon, 30 Mar 2026 07
- (CSTL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily Mon, 20 Apr 2026 07
- Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k - Investing.com hu, 05 Mar 2026 08
- $CSTL stock is up 20% today. Here's what we see in our data. - Quiver Quantitative ue, 04 Nov 2025 08
- Castle Biosciences (NASDAQ:CSTL) Shares Down 7% - What's Next? - MarketBeat Fri, 10 Apr 2026 07
- Castle Biosciences, Inc.'s (NASDAQ:CSTL) 44% Share Price Surge Not Quite Adding Up - simplywall.st hu, 06 Nov 2025 08
- After the close on May 6, Castle Biosciences will break down Q1 - Stock Titan Wed, 15 Apr 2026 11
- Are You Looking for a Top Momentum Pick? Why Castle Biosciences, Inc. (CSTL) is a Great Choice - Yahoo Finance Fri, 23 Jan 2026 08
- Castle Biosciences, Inc. (CSTL) Stock Analysis: A Healthcare Innovator with Strong Buy Ratings and 9.13% Upside Potential - DirectorsTalk Interviews Fri, 23 Jan 2026 08
- Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat Fri, 17 Apr 2026 06
- Employees put Castle Biosciences on USA TODAY's workplace list again - Stock Titan Fri, 10 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
344.23
+3.66%
|
332.07
+51.09%
|
219.79
+60.38%
|
137.04
|
| Operating Revenue |
|
344.23
+3.66%
|
332.07
+51.09%
|
219.79
+60.38%
|
137.04
|
| Cost Of Revenue |
|
71.03
+17.98%
|
60.20
+33.84%
|
44.98
+40.53%
|
32.01
|
| Reconciled Cost Of Revenue |
|
65.09
+17.68%
|
55.31
+32.76%
|
41.66
+40.14%
|
29.73
|
| Gross Profit |
|
273.20
+0.49%
|
271.86
+55.52%
|
174.81
+66.43%
|
105.03
|
| Operating Expense |
|
316.01
+20.07%
|
263.19
+8.41%
|
242.78
+23.76%
|
196.17
|
| Research And Development |
|
51.85
-0.37%
|
52.04
-2.94%
|
53.62
+19.41%
|
44.90
|
| Selling General And Administration |
|
229.32
+14.63%
|
200.05
+11.04%
|
180.15
+25.98%
|
143.00
|
| Selling And Marketing Expense |
|
138.12
+11.86%
|
123.47
+8.63%
|
113.66
+31.23%
|
86.61
|
| General And Administrative Expense |
|
91.21
+19.10%
|
76.58
+15.17%
|
66.50
+17.91%
|
56.40
|
| Other Gand A |
|
91.21
+19.10%
|
76.58
+15.17%
|
66.50
+17.91%
|
56.40
|
| Total Expenses |
|
387.04
+19.68%
|
323.40
+12.38%
|
287.76
+26.11%
|
228.18
|
| Operating Income |
|
-42.81
-593.77%
|
8.67
+112.75%
|
-67.98
+25.42%
|
-91.14
|
| Total Operating Income As Reported |
|
-42.81
-593.77%
|
8.67
+112.75%
|
-67.98
+6.70%
|
-72.86
|
| EBITDA |
|
11.34
-70.26%
|
38.14
+184.71%
|
-45.02
+22.83%
|
-58.34
|
| Normalized EBITDA |
|
9.88
-73.72%
|
37.58
+183.47%
|
-45.02
+41.25%
|
-76.63
|
| Reconciled Depreciation |
|
40.77
+154.87%
|
16.00
+29.74%
|
12.33
+16.95%
|
10.54
|
| EBIT |
|
-29.43
-232.91%
|
22.14
+138.60%
|
-57.35
+16.74%
|
-68.89
|
| Total Unusual Items |
|
1.47
+164.14%
|
0.56
|
0.00
-100.00%
|
18.29
|
| Total Unusual Items Excluding Goodwill |
|
1.47
+164.14%
|
0.56
|
0.00
-100.00%
|
18.29
|
| Special Income Charges |
|
—
|
0.00
|
0.00
-100.00%
|
18.29
|
| Restructuring And Mergern Acquisition |
|
—
|
0.00
|
0.00
+100.00%
|
-18.29
|
| Net Income |
|
-24.16
-232.41%
|
18.25
+131.75%
|
-57.47
+14.41%
|
-67.14
|
| Pretax Income |
|
-29.51
-236.87%
|
21.56
+137.59%
|
-57.37
+16.75%
|
-68.90
|
| Net Non Operating Interest Income Expense |
|
11.69
-5.29%
|
12.34
+16.27%
|
10.61
+168.59%
|
3.95
|
| Interest Expense Non Operating |
|
0.09
-85.10%
|
0.58
+5145.45%
|
0.01
-35.29%
|
0.02
|
| Net Interest Income |
|
11.69
-5.29%
|
12.34
+16.27%
|
10.61
+168.59%
|
3.95
|
| Interest Expense |
|
0.09
-85.10%
|
0.58
+5145.45%
|
0.01
-35.29%
|
0.02
|
| Interest Income Non Operating |
|
11.77
-8.86%
|
12.92
+21.59%
|
10.62
+167.72%
|
3.97
|
| Interest Income |
|
11.77
-8.86%
|
12.92
+21.59%
|
10.62
+167.72%
|
3.97
|
| Other Income Expense |
|
1.61
+190.09%
|
0.56
|
—
|
18.29
|
| Other Non Operating Income Expenses |
|
0.14
-74.05%
|
0.56
|
—
|
—
|
| Gain On Sale Of Security |
|
1.47
+164.14%
|
0.56
|
—
|
—
|
| Tax Provision |
|
-5.36
-261.37%
|
3.32
+3186.14%
|
0.10
+105.72%
|
-1.77
|
| Tax Rate For Calcs |
|
0.00
+17.60%
|
0.00
-26.71%
|
0.00
+719.35%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.27
+210.63%
|
0.09
|
0.00
-100.00%
|
0.47
|
| Net Income Including Noncontrolling Interests |
|
-24.16
-232.41%
|
18.25
+131.75%
|
-57.47
+14.41%
|
-67.14
|
| Net Income From Continuing Operation Net Minority Interest |
|
-24.16
-232.41%
|
18.25
+131.75%
|
-57.47
+14.41%
|
-67.14
|
| Net Income From Continuing And Discontinued Operation |
|
-24.16
-232.41%
|
18.25
+131.75%
|
-57.47
+14.41%
|
-67.14
|
| Net Income Continuous Operations |
|
-24.16
-232.41%
|
18.25
+131.75%
|
-57.47
+14.41%
|
-67.14
|
| Normalized Income |
|
-25.36
-242.66%
|
17.78
+130.93%
|
-57.47
+32.36%
|
-84.96
|
| Net Income Common Stockholders |
|
-24.16
-232.41%
|
18.25
+131.75%
|
-57.47
+14.41%
|
-67.14
|
| Diluted EPS |
|
-0.83
-233.87%
|
0.62
+128.97%
|
-2.14
+17.05%
|
-2.58
|
| Basic EPS |
|
-0.83
-225.76%
|
0.66
+130.84%
|
-2.14
+17.05%
|
-2.58
|
| Basic Average Shares |
|
28.99
+4.36%
|
27.78
+3.63%
|
26.80
+2.87%
|
26.05
|
| Diluted Average Shares |
|
28.99
-0.92%
|
29.25
+9.15%
|
26.80
+2.87%
|
26.05
|
| Diluted NI Availto Com Stockholders |
|
-24.16
-232.41%
|
18.25
+131.75%
|
-57.47
+14.41%
|
-67.14
|
| Amortization |
|
34.84
+213.69%
|
11.11
+23.22%
|
9.01
+9.04%
|
8.27
|
| Amortization Of Intangibles Income Statement |
|
34.84
+213.69%
|
11.11
+23.22%
|
9.01
+9.04%
|
8.27
|
| Depreciation Amortization Depletion Income Statement |
|
34.84
+213.69%
|
11.11
+23.22%
|
9.01
+9.04%
|
8.27
|
| Depreciation And Amortization In Income Statement |
|
34.84
+213.69%
|
11.11
+23.22%
|
9.01
+9.04%
|
8.27
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
578.56
+8.91%
|
531.24
+17.18%
|
453.34
+1.34%
|
447.33
|
| Current Assets |
|
361.10
+0.26%
|
360.15
+21.82%
|
295.63
+1.15%
|
292.29
|
| Cash Cash Equivalents And Short Term Investments |
|
299.50
+2.17%
|
293.13
+20.58%
|
243.10
-6.00%
|
258.62
|
| Cash And Cash Equivalents |
|
116.73
-2.49%
|
119.71
+21.11%
|
98.84
-19.61%
|
122.95
|
| Other Short Term Investments |
|
182.78
+5.39%
|
173.42
+20.22%
|
144.26
+6.32%
|
135.68
|
| Receivables |
|
43.38
-15.30%
|
51.22
+33.72%
|
38.30
+63.15%
|
23.48
|
| Accounts Receivable |
|
43.38
-15.30%
|
51.22
+33.72%
|
38.30
+63.15%
|
23.48
|
| Inventory |
|
10.25
+26.05%
|
8.13
+2.43%
|
7.94
+99.55%
|
3.98
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
7.96
+3.72%
|
7.67
+21.92%
|
6.29
+1.37%
|
6.21
|
| Total Non Current Assets |
|
217.46
+27.11%
|
171.08
+8.48%
|
157.71
+1.72%
|
155.04
|
| Net PPE |
|
112.24
+78.99%
|
62.71
+66.16%
|
37.74
+42.43%
|
26.50
|
| Gross PPE |
|
130.53
+72.80%
|
75.54
+64.75%
|
45.85
+33.50%
|
34.34
|
| Accumulated Depreciation |
|
-18.30
-42.58%
|
-12.83
-58.22%
|
-8.11
-3.35%
|
-7.85
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Land And Improvements |
|
7.25
+0.00%
|
7.25
|
0.00
|
—
|
| Machinery Furniture Equipment |
|
9.57
+8.15%
|
8.85
+37.27%
|
6.45
+7.49%
|
6.00
|
| Construction In Progress |
|
51.06
+431.09%
|
9.61
+1409.26%
|
0.64
-50.04%
|
1.27
|
| Other Properties |
|
47.83
+35.81%
|
35.22
+22.37%
|
28.78
+31.39%
|
21.90
|
| Leases |
|
14.83
+1.49%
|
14.62
+46.31%
|
9.99
+93.19%
|
5.17
|
| Goodwill And Other Intangible Assets |
|
99.57
-6.26%
|
106.23
-9.47%
|
117.33
-7.13%
|
126.35
|
| Goodwill |
|
10.69
+0.00%
|
10.69
+0.00%
|
10.69
+0.00%
|
10.69
|
| Other Intangible Assets |
|
88.88
-6.97%
|
95.54
-10.41%
|
106.64
-7.79%
|
115.66
|
| Non Current Accounts Receivable |
|
1.88
+104.58%
|
0.92
-22.92%
|
1.19
+9.57%
|
1.09
|
| Other Non Current Assets |
|
3.77
+206.92%
|
1.23
-14.72%
|
1.44
+29.73%
|
1.11
|
| Total Liabilities Net Minority Interest |
|
107.68
+42.82%
|
75.40
+21.47%
|
62.07
+28.83%
|
48.18
|
| Current Liabilities |
|
68.68
+39.04%
|
49.39
+3.62%
|
47.67
+31.94%
|
36.13
|
| Payables And Accrued Expenses |
|
24.60
+108.12%
|
11.82
-26.51%
|
16.08
+85.33%
|
8.68
|
| Payables |
|
18.71
+171.13%
|
6.90
-35.32%
|
10.67
+125.51%
|
4.73
|
| Accounts Payable |
|
18.71
+171.13%
|
6.90
-32.79%
|
10.27
+117.04%
|
4.73
|
| Current Accrued Expenses |
|
5.89
+19.70%
|
4.92
-9.16%
|
5.41
+37.17%
|
3.95
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
39.21
+16.08%
|
33.78
+13.20%
|
29.84
+18.14%
|
25.26
|
| Total Tax Payable |
|
—
|
1.08
+168.33%
|
0.40
+983.78%
|
0.04
|
| Current Debt And Capital Lease Obligation |
|
1.74
-10.34%
|
1.94
+70.89%
|
1.14
-36.02%
|
1.78
|
| Current Debt |
|
0.42
+50.00%
|
0.28
|
—
|
—
|
| Other Current Borrowings |
|
0.42
+50.00%
|
0.28
|
—
|
—
|
| Current Capital Lease Obligation |
|
1.32
-20.42%
|
1.67
+46.44%
|
1.14
-36.02%
|
1.78
|
| Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Current Deferred Revenue |
|
—
|
—
|
—
|
—
|
| Other Current Liabilities |
|
3.13
+68.97%
|
1.85
+205.28%
|
0.61
+46.02%
|
0.41
|
| Total Non Current Liabilities Net Minority Interest |
|
39.01
+49.98%
|
26.01
+80.56%
|
14.40
+19.53%
|
12.05
|
| Long Term Debt And Capital Lease Obligation |
|
35.17
+44.14%
|
24.40
+71.86%
|
14.20
+22.15%
|
11.62
|
| Long Term Debt |
|
9.64
-1.08%
|
9.74
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
25.53
+74.20%
|
14.66
+3.23%
|
14.20
+22.15%
|
11.62
|
| Non Current Deferred Liabilities |
|
2.33
+45.30%
|
1.61
+680.10%
|
0.21
-51.87%
|
0.43
|
| Non Current Deferred Revenue |
|
—
|
—
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
2.33
+45.30%
|
1.61
+680.10%
|
0.21
-51.87%
|
0.43
|
| Other Non Current Liabilities |
|
1.50
|
—
|
—
|
—
|
| Stockholders Equity |
|
470.87
+3.30%
|
455.83
+16.50%
|
391.27
-1.97%
|
399.15
|
| Common Stock Equity |
|
470.87
+3.30%
|
455.83
+16.50%
|
391.27
-1.97%
|
399.15
|
| Capital Stock |
|
0.03
+7.14%
|
0.03
+3.70%
|
0.03
+0.00%
|
0.03
|
| Common Stock |
|
0.03
+7.14%
|
0.03
+3.70%
|
0.03
+0.00%
|
0.03
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
29.69
+4.22%
|
28.48
+3.91%
|
27.41
+3.23%
|
26.55
|
| Ordinary Shares Number |
|
29.69
+4.22%
|
28.48
+3.91%
|
27.41
+3.23%
|
26.55
|
| Additional Paid In Capital |
|
694.86
+5.97%
|
655.70
+7.58%
|
609.48
+8.76%
|
560.41
|
| Retained Earnings |
|
-224.28
-12.07%
|
-200.13
+8.36%
|
-218.37
-35.71%
|
-160.91
|
| Gains Losses Not Affecting Retained Earnings |
|
0.27
+16.09%
|
0.23
+69.12%
|
0.14
+135.70%
|
-0.38
|
| Other Equity Adjustments |
|
0.27
+16.09%
|
0.23
+69.12%
|
0.14
+135.70%
|
-0.38
|
| Total Equity Gross Minority Interest |
|
470.87
+3.30%
|
455.83
+16.50%
|
391.27
-1.97%
|
399.15
|
| Total Capitalization |
|
480.51
+3.21%
|
465.58
+18.99%
|
391.27
-1.97%
|
399.15
|
| Working Capital |
|
292.42
-5.90%
|
310.76
+25.32%
|
247.97
-3.20%
|
256.16
|
| Invested Capital |
|
480.93
+3.24%
|
465.86
+19.06%
|
391.27
-1.97%
|
399.15
|
| Total Debt |
|
36.91
+40.12%
|
26.34
+71.79%
|
15.34
+14.44%
|
13.40
|
| Capital Lease Obligations |
|
26.86
+64.55%
|
16.32
+6.43%
|
15.34
+14.44%
|
13.40
|
| Net Tangible Assets |
|
371.30
+6.20%
|
349.61
+27.62%
|
273.93
+0.41%
|
272.80
|
| Tangible Book Value |
|
371.30
+6.20%
|
349.61
+27.62%
|
273.93
+0.41%
|
272.80
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
64.35
-0.80%
|
64.87
+1252.97%
|
-5.63
+86.49%
|
-41.66
|
| Cash Flow From Continuing Operating Activities |
|
64.35
-0.80%
|
64.87
+1252.97%
|
-5.63
+86.49%
|
-41.66
|
| Net Income From Continuing Operations |
|
-24.16
-232.41%
|
18.25
+131.75%
|
-57.47
+14.41%
|
-67.14
|
| Depreciation Amortization Depletion |
|
40.77
+154.87%
|
16.00
+29.74%
|
12.33
+16.95%
|
10.54
|
| Depreciation |
|
5.93
+21.30%
|
4.89
+47.45%
|
3.32
+45.61%
|
2.28
|
| Amortization Cash Flow |
|
34.84
+213.69%
|
11.11
+23.22%
|
9.01
+9.04%
|
8.27
|
| Depreciation And Amortization |
|
40.77
+154.87%
|
16.00
+29.74%
|
12.33
+16.95%
|
10.54
|
| Amortization Of Intangibles |
|
34.84
+213.69%
|
11.11
+23.22%
|
9.01
+9.04%
|
8.27
|
| Other Non Cash Items |
|
0.15
-42.91%
|
0.27
-57.80%
|
0.64
+103.50%
|
-18.13
|
| Stock Based Compensation |
|
45.89
-8.80%
|
50.32
-1.76%
|
51.22
+41.02%
|
36.32
|
| Deferred Tax |
|
-6.23
-544.54%
|
1.40
+728.25%
|
-0.22
+88.12%
|
-1.88
|
| Deferred Income Tax |
|
-6.23
-544.54%
|
1.40
+728.25%
|
-0.22
+88.12%
|
-1.88
|
| Operating Gains Losses |
|
-1.47
-164.14%
|
-0.56
|
—
|
—
|
| Gain Loss On Investment Securities |
|
-1.47
-164.14%
|
-0.56
|
—
|
—
|
| Change In Working Capital |
|
13.60
+196.29%
|
-14.12
-113.05%
|
-6.63
-94614.29%
|
-0.01
|
| Change In Receivables |
|
6.88
+154.39%
|
-12.64
+15.32%
|
-14.93
-140.11%
|
-6.22
|
| Changes In Account Receivables |
|
6.88
+154.39%
|
-12.64
+15.32%
|
-14.93
-140.11%
|
-6.22
|
| Change In Inventory |
|
-2.14
-1009.84%
|
-0.19
+95.13%
|
-3.96
-135.83%
|
-1.68
|
| Change In Prepaid Assets |
|
-0.54
+52.36%
|
-1.14
-162.53%
|
-0.43
+64.46%
|
-1.22
|
| Change In Payables And Accrued Expense |
|
9.68
+2290.05%
|
-0.44
-103.56%
|
12.43
+53.23%
|
8.11
|
| Change In Accrued Expense |
|
6.60
+67.99%
|
3.93
-41.57%
|
6.73
-10.70%
|
7.53
|
| Change In Payable |
|
3.08
+170.40%
|
-4.37
-176.61%
|
5.71
+880.58%
|
0.58
|
| Change In Account Payable |
|
3.08
+170.40%
|
-4.37
-176.61%
|
5.71
+880.58%
|
0.58
|
| Change In Other Working Capital |
|
—
|
—
|
4.59
-46.00%
|
8.49
|
| Change In Other Current Assets |
|
1.01
-36.49%
|
1.58
+369.39%
|
-0.59
-136.54%
|
1.61
|
| Change In Other Current Liabilities |
|
-1.27
+1.09%
|
-1.29
-251.29%
|
0.85
+240.13%
|
-0.61
|
| Investing Cash Flow |
|
-60.37
-20.40%
|
-50.14
-209.81%
|
-16.18
+90.28%
|
-166.54
|
| Cash Flow From Continuing Investing Activities |
|
-60.37
-20.40%
|
-50.14
-209.81%
|
-16.18
+90.28%
|
-166.54
|
| Net PPE Purchase And Sale |
|
-35.98
-27.09%
|
-28.31
-108.02%
|
-13.61
-150.29%
|
-5.44
|
| Purchase Of PPE |
|
-36.02
-27.17%
|
-28.33
-107.96%
|
-13.62
-141.85%
|
-5.63
|
| Sale Of PPE |
|
0.04
+150.00%
|
0.02
+38.46%
|
0.01
-93.33%
|
0.20
|
| Capital Expenditure |
|
-36.02
-27.17%
|
-28.33
-107.96%
|
-13.62
-141.85%
|
-5.63
|
| Net Investment Purchase And Sale |
|
2.02
+109.25%
|
-21.83
-747.73%
|
-2.58
+98.09%
|
-134.69
|
| Purchase Of Investment |
|
-188.71
+8.27%
|
-205.73
-8.81%
|
-189.07
-40.38%
|
-134.69
|
| Sale Of Investment |
|
190.73
+3.72%
|
183.90
-1.39%
|
186.50
|
0.00
|
| Net Business Purchase And Sale |
|
-18.73
|
0.00
|
0.00
+100.00%
|
-26.97
|
| Purchase Of Business |
|
-18.73
|
0.00
|
0.00
+100.00%
|
-26.97
|
| Net Other Investing Changes |
|
-7.68
|
—
|
—
|
0.55
|
| Financing Cash Flow |
|
-6.96
-213.37%
|
6.14
+367.15%
|
-2.30
-251.68%
|
1.51
|
| Cash Flow From Continuing Financing Activities |
|
-6.96
-213.37%
|
6.14
+367.15%
|
-2.30
-251.68%
|
1.51
|
| Net Issuance Payments Of Debt |
|
0.07
-99.24%
|
9.90
+7073.94%
|
-0.14
-16.39%
|
-0.12
|
| Issuance Of Debt |
|
0.19
-98.10%
|
10.00
|
0.00
|
0.00
|
| Repayment Of Debt |
|
-0.12
-18.56%
|
-0.10
+31.69%
|
-0.14
-16.39%
|
-0.12
|
| Long Term Debt Issuance |
|
0.19
-98.10%
|
10.00
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
-0.12
-18.56%
|
-0.10
+31.69%
|
-0.14
-16.39%
|
-0.12
|
| Net Long Term Debt Issuance |
|
0.07
-99.24%
|
9.90
+7073.94%
|
-0.14
-16.39%
|
-0.12
|
| Net Common Stock Issuance |
|
—
|
—
|
—
|
—
|
| Proceeds From Stock Option Exercised |
|
4.62
-7.52%
|
5.00
+67.83%
|
2.98
-10.44%
|
3.33
|
| Net Other Financing Charges |
|
-11.66
-33.04%
|
-8.76
-70.67%
|
-5.13
-204.15%
|
-1.69
|
| Changes In Cash |
|
-2.98
-114.28%
|
20.87
+186.56%
|
-24.11
+88.34%
|
-206.69
|
| Beginning Cash Position |
|
119.71
+21.11%
|
98.84
-19.61%
|
122.95
-62.70%
|
329.63
|
| End Cash Position |
|
116.73
-2.49%
|
119.71
+21.11%
|
98.84
-19.61%
|
122.95
|
| Free Cash Flow |
|
28.33
-22.48%
|
36.54
+289.85%
|
-19.25
+59.30%
|
-47.29
|
| Interest Paid Supplemental Data |
|
0.06
-86.41%
|
0.43
+3845.45%
|
0.01
-31.25%
|
0.02
|
| Income Tax Paid Supplemental Data |
|
1.60
-36.04%
|
2.50
+1164.14%
|
0.20
+65.00%
|
0.12
|
| Amortization Of Securities |
|
-4.22
+36.89%
|
-6.68
-21.74%
|
-5.49
-301.39%
|
-1.37
|
| Common Stock Issuance |
|
—
|
—
|
—
|
—
|
| Issuance Of Capital Stock |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-08 View
- 42026-03-30 View
- 42026-03-30 View
- 42026-03-19 View
- 42026-03-17 View
- 42026-03-16 View
- 42026-03-13 View
- 42026-03-09 View
- 42026-03-09 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-05 View
- 10-K2026-02-26 View
- 8-K2026-02-26 View
- 42026-02-05 View
- 42026-01-22 View
- 42026-01-14 View
- 42026-01-14 View
- 42026-01-14 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|